Assessing the impact of an intravenous biosensor on the prevention of infusate injuries throughout a child’s hospitalisation: A Type 1 Hybrid Randomised Controlled Trial

niversity of Queensland0 个研究点目标入组 532 人开始时间: 2023年5月25日最近更新: 2023年12月12日

适应症

试验速览

暂无简介。

•1) Neonates (greater than or equal to 1250 grams + physically able to fit the IV sensor on the limb)
•2) Infants younger than one year
•3) Have an existing or new peripheral IVs (including long and traditional peripheral IV) inserted in the distal half of a limb (i.e. proximal to antecubital for upper limb).
•4) Peripheral IV anticipated to be in situ for >24 hours,
•5) Planned administration via the study peripheral IV of either:
•-continuous fluids (for 4 hours or more) including blood products.
•-antimicrobials, or
•-intermediate to high risk infusates .

•1) Planned administration of lipid-based infusate via study peripheral IV (e.g., propofol).
•2) Other types of vascular access devices, including midline catheters, peripheral arterial catheters and central venous catheters
•3) Pre-existing skin condition effecting study peripheral IV site, e,g., i) atopic dermatitis or extensive erythema toxicum, ii) infectious diseases such as Staphylococcal scalded skin syndrome; iii) burn (e.g., heat, decontamination); iv) inherited conditions such as epidermolysis bullosa, ichthyosis and aplasia cutis congenita
•4) Previously enrolled in this study and randomized to one of the treatment conditions
•5) Currently receiving end of life and/or redirection of care.

发起方

niversity of Queensland